Axxam S.p.A was founded as an independent and privately owned company in November 2001 as a spin-off from the Bayer Group. Our main expertise at the time was in the development of cell-based and biochemical assays for High-Throughput Screening ( HTS). The company rapidly grew and expanded its operations to include a first fully automated HTS station in 2005 followed by a second one the year after.
In the period from 2001 to 2007 the company was mainly focused on the provision of services to third parties and the development of IP-protected technologies for Freedom to Operate (FTO) and out-licensing.
Starting in late 2008, Axxam expanded its business model by establishing its own portfolio of internal discovery programs against attractive biomedical targets, which are then out-licensed at the lead candidate stage to a collaborative/licensing partner. Chemistry laboratories were established in Naples, Italy in 2010 with the aim of supporting the internal discovery programs
Concurrently, Axxam also expanded its range of services to include electrophysiology (manual and automated), access to a chemical compound collection (AXXDIV2.0), and more recently, radiometric, High Content Screening, compounds storage and management.
In May 2016, Axxam expanded to USA opening a business office at the Cambridge Innovation Center (CIC) in Cambridge, Mass.